Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951326 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
A Phase 3 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
NCT01951326 is a Phase 3 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 331 participants.
The verdict
NCT01951326, a Phase 3 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
Study Summary
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
Interventions
- DRUG Placebo
- DRUG RHB-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2013-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951326
The ClinicalTrials.gov registry entry for NCT01951326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01951326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01951326 about?
NCT01951326 is a clinical study titled "Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease". The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
What is the current status of trial NCT01951326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2013-09. Estimated completion is 2019-08.
What interventions are being tested in trial NCT01951326?
The interventions under investigation include: Placebo (DRUG), RHB-104 (DRUG).
Who is sponsoring clinical trial NCT01951326?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.